Early Rabies Vaccine Immunization in Primary School Children

Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01107275

Acronym

I49P1

Enrollment

703

Registered

2010-04-20

Start date

2002-11-30

Completion date

2008-11-30

Last updated

2010-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies Prevention

Keywords

Rabies, PCECV, pre-exposure immunization, intradermal, children

Brief summary

700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken for rabies virus neutralizing antibody determination on day 49. All subjects were randomized to receive 2 booster doses (the recommended vaccination schedule for pre-immunized individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood was taken before and after booster for up to one year.Safety and tolerability of the vaccine was assessed and persistence of immune response up to 1 year after the booster doses.

Interventions

BIOLOGICALrabies vaccine

intradermal vaccination

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

5 Years to 8 Years

Healthy volunteers

Yes

Inclusion criteria

Male and female 5-8 years old school children will be included in the study if: * Their parents or legal guardians have given the written informed consent prior to study entry; * They are in good health at time of study entry as determined by medical history, physical examination and clinical judgment of the investigator; * They are available for all the visits scheduled in the study.

Exclusion criteria

Subjects are not to be enrolled into the study if: * They have a history of rabies immunization; * They have an acute infectious disease at the time of study entry; * They are under treatment with parenteral and/or oral steroids, immunosuppressive drugs, phenytoin or other specific anti-inflammatory drugs, or have taken chloroquine during the two month period before enrolment; * They have a known immunodeficiency or an autoimmune disease; * They have a known hypersensitivity to neomycin, tetracycline or amphotericin-B; * They have planned surgery during the first study period (49 days); * They are participating in any other trial of an investigational agent; * They have any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives. * The family plans to leave the area of the study site before the end of the study period.

Design outcomes

Primary

Measure	Time frame	Description
rabies virus neuralizing antibody, assessed by RFFIT	seven days after the first booster dose	rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)

Secondary

Measure	Time frame	Description
rabies virus neuralizing antibody, assessed by RFFIT	one year after the first booster dose	rabies virus neuralizing antibody concentrations were measured in serum samples using the rapid fluorescent focus inhibition test (RFFIT)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026